ВПЛ-тестування у цервікальному скринінгу
DOI:
https://doi.org/10.15574/HW.2016.112.100Ключові слова:
рак шийки матки, цервікальний скринінг, традиційна цитологія, рідинна цитологія, ПАП-тест, вірус папіломи людиниАнотація
У статті представлені сучасні лабораторні аспекти цервікального скринінгу, що включають оцінку інфікування вірусом папіломи людини (ВПЛ) високого канцерогенного ризику.
Ключові слова: рак шийки матки, цервікальний скринінг, традиційна цитологія, рідинна цитологія, ПАП-тест, вірус папіломи людини.
Посилання
Wright TC, Stoler MH, Sharma A et al. 2011. Evaluation of HPV-16 and HPV-18 genotyping for the triage of women with high-risk HPV+ cytology-negative results. Am J Clin Pathol 136:578–586. http://dx.doi.org/10.1309/AJCPTUS5EXAS6DKZ; PMid:21917680
FDA Approves First Human Papillomavirus Test for Primary Cervical Cancer Screening. News. Silver Spring, Md: Food and Drug Administration, 2014. Available online. Last accessed September 18, 2014.
Cuzick J, Clavel C, Petry KU, Meijer CJ, Hoyer H, Ratnam S et al. 2006. Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int J Cancer 119:1095–101. http://dx.doi.org/10.1002/ijc.21955; PMid:16586444
Li N, Franceschi S, Howell-Jones R, Snijders PJ, Clifford GM. 2011. Human papillomavirus type distribution in 30,848 invasive cervical cancers worldwide: Variation by geographical region, histological type and year of publication. Int J Cancer 128:927–35. http://dx.doi.org/10.1002/ijc.25396; PMid:20473886
Bulk S, Visser O, Rozendaal L, Verheijen RH, Meijer CJ. 2003. Incidence and survival rate of women with cervical cancer in the Greater Amsterdam area. Br J Cancer 89:834–9. http://dx.doi.org/10.1038/sj.bjc.6601157; PMid:12942114 PMCid:PMC2394479
Confortini M, Bergeron C, Desai M, Negri G, Dalla PP, Montanari G et al. 2010. Accuracy of liquid-based cytology: comparison of the results obtained within a randomized controlled trial (the New Technologies for Cervical Cancer Screening Study) and an external group of experts. Cancer Cytopathol 118:203–8. http://dx.doi.org/10.1002/cncy.20081; PMid:20731006
Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV et al. 1999. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 189:12–9. http://dx.doi.org/10.1002/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F
Petry KU, Schmidt D, Scherbring S, Luyten A, Reinecke-Luthge A, Bergeron C et al. 2011. Triaging Pap cytology negative, HPV positive cervical cancer screening results with p16/Ki-67 Dual-staine cytology. Gynecol Oncol.
Munoz N, Bosch FX, Castellsague X, Diaz M, de Sanjose S, Hammouda D et al. 2004. Against which human papillomavirus types shall we vaccinate and screen? the international perspective. Int J Cancer 111:278–85. http://dx.doi.org/10.1002/ijc.20244; PMid:15197783
Overmeer RM, Henken FE, Bierkens M, Wilting SM, Timmerman I, Meijer CJ et al. 2009. Repression of MAL tumour suppressor activity by promoter methylation during cervical carcinogenesis. J Pathol 219:327–36. http://dx.doi.org/10.1002/path.2598; PMid:19662663
European Commission. European Guidelines for Quality Assurance in Cervical Cancer Screening. 2nd ed. Arbyn M, Anttila A, Jordan J, Ronco G, Schenck U, Segnan N, Wiener H, Herbert A, Daniel J, von Karsa L, European Commission, editors. Luxembourg: Office for Official Publications of the European Communities, 2008: 1–291.
Arbyn M, Sasieni P, Meijer CJ, Clavel C, Koliopoulos G, Dillner J. 2006. Chapter 9: Clinical applications of HPV testing: a summary of meta-analyses. Vaccine 24 (3):S78–S89. http://dx.doi.org/10.1016/j.vaccine.2006.05.117; PMid:16950021
